Genmab Merus acquisition for $8 billion enhances its oncology portfolio with innovative therapies like Petosemtamab.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
Glenmark Hengrui licensing deal secures $1 billion, granting exclusive rights and impacting the pharmaceutical market.
Pfizer Metsera acquisition enhances its obesity drug portfolio with promising GLP-1 and amylin candidates for $4.9 billion.
Biogen Alcyone acquisition grants access to implantable device, potentially easing RNA drug delivery for treatments like Spinraza.
Arvinas out-license vepdegestrant with Pfizer, impacting their partnership and market strategy.
Roche 89bio deal involves a $2.4 billion acquisition, targeting MASH with a late-stage drug that could impact the market significantly.
AbbVie acquires bretisilocin for up to $1.2 billion, marking a significant move in psychedelic treatments.
Novartis Monte Rosa partnership focuses on immunology, potentially worth $5.7 billion.
Avadel XWPharma partnership secures global rights to valiloxybate, targeting narcolepsy and idiopathic hypersomnia.
Enlaza Vertex collaboration forms a $2.4 billion deal to advance autoimmune therapies using War-Lock technology.